600664.SH
哈药股份
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 8.22
+0.61%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 16.0B | 16.0B | 16.2B | 15.5B | 13.8B |
| Cost of Revenue | 11.9B | 11.8B | 11.6B | 11.4B | 10.4B |
| Gross Profit | 4.0B | 4.1B | 4.6B | 4.1B | 3.4B |
| Operating Expenses | |||||
| R&D Expense | 140.9M | 145.0M | 136.4M | 106.0M | 115.8M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 846.9M | 853.7M | 836.1M | 839.5M | 818.9M |
| Selling & Marketing Expense | 2.3B | 2.4B | 2.6B | 2.3B | 1.8B |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 3.5B | 3.5B | 3.7B | 3.4B | 2.9B |
| Cost and Expenses | 15.4B | 15.3B | 15.3B | 14.8B | 13.3B |
| Operating Income (EBIT) | 522.1M | 586.0M | 890.2M | 659.6M | 695.8M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 507.5M | 572.7M | 875.0M | 650.5M | 701.2M |
| Income Tax Expense | 166.4M | 174.0M | 184.4M | 176.3M | 188.9M |
| Bottom Line | |||||
| Net Income | 309.8M | 361.6M | 628.8M | 395.3M | 465.2M |
| Earnings from Cont. Ops | 341.1M | 398.8M | 690.6M | 474.2M | 512.2M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 309.8M | 361.6M | 628.8M | 395.3M | 465.2M |
| Per Share | |||||
| Basic EPS | CN¥0.12 | CN¥0.14 | CN¥0.25 | CN¥0.16 | CN¥0.19 |
| Diluted EPS | CN¥0.12 | CN¥0.14 | CN¥0.25 | CN¥0.16 | CN¥0.18 |
| Revenue Per Share | CN¥5.94 | CN¥6.18 | CN¥6.43 | CN¥6.26 | CN¥5.64 |
| Shares | |||||
| Basic Shares Outstanding | 2.7B | 2.6B | 2.5B | 2.5B | 2.4B |
| Diluted Shares Outstanding | 2.7B | 2.6B | 2.5B | 2.5B | 2.4B |
| Profitability Metrics | |||||
| EBITDA | — | 820.2M | 1.1B | 927.0M | 970.2M |
| D&A | — | 234.2M | 245.4M | 267.4M | 274.4M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026